skip to content
Primary navigation


Drug - Lartruvo™ (olaratumab) [Eli Lilly]

June 2017

Therapeutic area - Oncology

Approval criteria

  • Patient must be 18 years of page or older AND
  • Patient has a diagnosis of soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate AND
  • Radiotherapy or surgery is not a treatment option AND
  • Must use in combination with doxorubicin for the first 8 cycles AND
  • Patient’s current ECOG (Eastern Cooperative Oncology Group) performance status is 0 to 2 AND
  • At time of request, provider must attest that reproductive health counseling is provided to patients and their partners of child bearing age
  • Initial approval is for 6 months

Renewal criteria

  • Absence of unacceptable toxicity including grade 3 or 4 infusion related reactions AND
  • Absence of disease progression
  • Renewal approval is for 6 months

Quantity limits

  • 15 mg/kg on days 1 and 8 of each 21-day cycle
  • Patient’s weight must be provided at time of request

Background information

Lartruvo is FDA-approved under accelerated approval pathway. Continued approval may be contingent upon verification and description of clinical benefit in the confirmatory trial.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top